Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Contract Packaging
... CAGR of 8.7% over the analysis period 2024-2030. Food & Beverage, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$55.4 Billion by the end of the ... Read More
-
Artificial Intelligence in Pharmaceutical
... 2030, growing at a CAGR of 30.1% over the analysis period 2024-2030. Hardware, one of the segments analyzed in the report, is expected to record a 31.6% CAGR and reach US$3.6 Billion by the end ... Read More
-
Bio Decontamination
... CAGR of 4.5% over the analysis period 2024-2030. Equipment, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$122.1 Million by the end of the analysis period. ... Read More
-
Analgesics
... 5.3% over the analysis period 2024-2030. Prescription, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$43.8 Billion by the end of the analysis period. Growth in ... Read More
-
Manual Filling Equipment
... at a CAGR of 6.7% over the analysis period 2024-2030. Food & Beverages, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.1 Billion by the end ... Read More
-
Anti-Platelet Agents
... CAGR of 6.7% over the analysis period 2024-2030. Hospital Pharmacies, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Pharmaceutical Contract Packaging
... at a CAGR of 5.8% over the analysis period 2024-2030. Primary Packaging, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$25.7 Billion by the end of ... Read More
-
Pharmaceutical Packaging
... CAGR of 8.2% over the analysis period 2024-2030. Plastics & Polymers, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$114.0 Billion by the end of the ... Read More
-
Pharmacy Automation
... CAGR of 6.9% over the analysis period 2024-2030. Medication Dispensing Systems, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$3.3 Billion by the end of the ... Read More
-
Tangential Flow Filtration
... at a CAGR of 12.0% over the analysis period 2024-2030. Single-Use Systems, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Non-alcoholic Steatohepatitis (NASH)
... at a CAGR of 55.7% over the analysis period 2024-2030. Vitamin E & Pioglitazone, one of the segments analyzed in the report, is expected to record a 45.3% CAGR and reach US$59.7 Billion by the ... Read More
-
Semi-Automatic Filling Equipment
... at a CAGR of 6.6% over the analysis period 2024-2030. Food & Beverages, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$2.0 Billion by the end ... Read More
-
Anticholinergic Drugs
... CAGR of 5.0% over the analysis period 2024-2030. Synthetic Compounds, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$6.6 Billion by the end of the analysis ... Read More
-
Analytical Standards
... CAGR of 6.6% over the analysis period 2024-2030. Pharmaceutical & Life Science Analysis Application, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$611.4 Million by the ... Read More
-
Healthcare Analytical Testing Services
... 2030, growing at a CAGR of 9.7% over the analysis period 2024-2030. Bioanalytical Testing Services, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$2.6 Billion by ... Read More
-
Lifestyle Drugs
... CAGR of 3.1% over the analysis period 2024-2030. Obesity, one of the segments analyzed in the report, is expected to record a 3.6% CAGR and reach US$21.4 Billion by the end of the analysis period. ... Read More
-
Microencapsulation
... 12.4% over the analysis period 2024-2030. Spray, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$10.2 Billion by the end of the analysis period. Growth in ... Read More
-
Contract Research Outsourcing
... at a CAGR of 7.9% over the analysis period 2024-2030. Clinical, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$61.2 Billion by the end of the ... Read More
-
Native Collagen
... CAGR of 5.9% over the analysis period 2024-2030. Bovine, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$130.6 Million by the end of the analysis period. ... Read More
-
Pharmaceutical Analytical Testing Outsourcing
... 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Bioanalytical Testing, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$6.4 Billion by the ... Read More
-
Pharmaceutical Cartridges
... CAGR of 6.8% over the analysis period 2024-2030. Glass, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$2.0 Billion by the end of the analysis period. ... Read More
-
Pharmaceutical Grade Silica Gel
... 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. Desiccant, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$81.0 Million by the end ... Read More
-
Sustained Release Excipients
... at a CAGR of 6.0% over the analysis period 2024-2030. Polymers, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.2 Billion by the end of the ... Read More
-
Anti-Allergy Drugs
... CAGR of 7.1% over the analysis period 2024-2030. Pharmacies, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Beta-Sitosterol
... 8.1% over the analysis period 2024-2030. Food Ingredients, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$510.6 Million by the end of the analysis period. Growth ... Read More
Research Assistance
